Nancy Reau, DDW 2021: Hepatic Manifestations of COVID-19
Access all of the content
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection.
Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021.
- Could you give us a brief overview of the spectrum of hepatic manifestations of COVID-19? (0:10)
- Which patients are most likely to have elevated ALT/AST elevation and bilirubin and how long do these elevated levels typically persist? (1:37)
- What are the consequences of these elevations in terms of liver injury and COVID mortality? (2:38)
- What have we learned about progressive cholangiopathy in COVID-19 patients? (3:20)
Disclosures: Prof. Nancy Reau has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of DDW 2021.
Share this Video
Related Videos In Liver Disorders
Arjan Bredenoord, UEG Week 2022: Analysis of the LIBERTY-EoE-TREET study of dupilumab in eosinophilic esophagitis
LIBERTY-EoE-TREET (NCT03633617) was a phase 3, randomized, 3-part study investigating the efficacy and safety of dupilumab in eosinophilic esophagitis (EoE). It was a pleasure to talk with Prof. Arjan Bredenoord (Amsterdam UMC, Amsterdam, the Netherlands) around his analysis of the LIBERTY-EoE-TREET study, looking at the efficacy of dupilumab in patients with EoE with and without […]
Maria Buti, EASL ILC 2022: Impact of bulevirtide on patient-reported outcomes
MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d’Hebron University Hospital, Barcelona, Spain) discusses the results from the exploratory analysis of MYR301, investigating the health-related quality of life (HRQOL) benefits of treatment […]
Thomas Berg, EASL: Unmet needs in diagnosis and treatment of hepatitis
touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D. Question: What are the unmet needs in diagnosis and treatment of hepatitis? (0:20) Disclosures: Dr Thomas Berg has received grant/research […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!